Stocks Health care XENE
NASDAQ · Health careXenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. brought in $0 of revenue over the twelve months to September 30, 2026, down 100.0% from a year earlier. It posted a net loss of $428.7M. In fiscal 2025 capital spending exceeded operating cash flow by $279.9M. At September 30, 2026 it held $82.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Xenon Pharmaceuticals Inc.
- Net worth
- Xenon Pharmaceuticals Inc. has a market value (market cap) of $4B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $7.5M, with a net loss of $345.9M. Over the 12 months to September 30, 2026: revenue $0, net loss $428.7M.
- Cash flow
- In fiscal 2025 operations used $279.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Xenon Pharmaceuticals Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Xenon Pharmaceuticals Inc. does
Xenon Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XENE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.5M | -$345.9M | -$4.36 | -$279.9M |
| 2024 | $0 | -$234.3M | -$3.01 | -$184.5M |
| 2023 | $0 | -$182.4M | -$2.73 | -$156.7M |
| 2022 | $9.4M | -$125.4M | -$2.06 | -$103.9M |
| 2021 | $18.4M | -$78.9M | -$1.77 | -$71.6M |
| 2020 | $32.2M | -$28.8M | -$0.81 | -$50.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where XENE ranks in Health care
Latest SEC filings
What Xenon Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 9, 2026
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 6, 2026Passive stake (5% or more) SCHEDULE 13G
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
Insider trades
What the people running Xenon Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $1.7M and sold $425.8K worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Kelly Thomas PatrickChief Financial Officer | Exercised options | 7,500 | - |
| September 30, 2026 | Mortimer IanPRESIDENT & CEO, Director | Bought | 30,000 | $1.1M |
| September 30, 2026 | Kelly Thomas PatrickChief Financial Officer | Bought | 15,000 | $559.7K |
| September 1, 2026 | Svoronos DawnDirector | Exercised options | 5,144 | $41.9K |
| August 28, 2026 | Kenney Christopher JohnChief Medical Officer | Soldpre-planned (10b5-1) | 6,368 | $383.1K |
| August 28, 2026 | Kenney Christopher JohnChief Medical Officer | Soldpre-planned (10b5-1) | 700 | $42.7K |
| August 11, 2026 | Gannon StevenDirector | Sold | 10,000 | $640.6K |
| June 5, 2026 | Cannon GillianDirector | Soldpre-planned (10b5-1) | 1,190 | $63.2K |
Who owns XENE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 10.3% | August 7, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 8.2% | November 6, 2026 |
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 6.26% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 315 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 9,647,998 | -1,170,493 |
| BlackRock, Inc. | 7,522,482 | +1,882,364 |
| Avoro Capital Advisors LLC | 5,777,777 | 0 |
| Polar Capital Holdings Plc | 4,570,556 | +165,244 |
| Driehaus Capital Management LLC | 4,418,557 | -73,096 |
| Jupiter Topco LLC | 4,186,519 | new |
| Jpmorgan Chase & Co | 2,617,360 | +693,750 |
| Capital International Investors | 2,361,639 | -313,088 |
| State Street Corp | 1,969,629 | +249,096 |
| Two Sigma Investments, LP | 1,642,848 | +1,036,763 |
| Deerfield Management Company, L.P. | 1,615,696 | 0 |
| Affinity Asset Advisors, LLC | 1,595,000 | -80,000 |
| Westfield Capital Management Co LP | 1,507,294 | +105,811 |
| Alliancebernstein L.P. | 1,562,276 | +158,979 |
| Franklin Resources Inc | 1,437,712 | +157,135 |
| Wellington Management Group Llp | 1,425,492 | -3,404,149 |
| Citadel Advisors LLC | 1,401,242 | -1,251,748 |
| Geode Capital Management, LLC | 1,370,114 | +277,182 |
| Siren, L.L.C. | 1,318,564 | 0 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,290,731 | -51,297 |
Insiders
11 insiders reported holding 147,255 shares in total, about $6.1M at the last price.
| Holder | Shares |
|---|---|
| Mortimer IanPRESIDENT & CEO, Director | 49,923 |
| Svoronos DawnDirector | 31,373 |
| Patou GaryDirector | 24,896 |
| Kelly Thomas PatrickChief Financial Officer | 22,500 |
| DiFabio AndreaChief Legal Officer | 7,301 |
| Gover Justin D.Director | 2,645 |
| Machado PatrickDirector | 2,645 |
| Garofalo Elizabeth A.Director | 2,645 |
| Gannon StevenDirector | 1,870 |
| Cannon GillianDirector | 1,455 |
Questions about XENE
What does Xenon Pharmaceuticals Inc. do?
Xenon Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as XENE. Its shares trade on NASDAQ under the ticker XENE.
What is Xenon Pharmaceuticals Inc.'s net worth?
Xenon Pharmaceuticals Inc. has a market value (market cap) of $4B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Xenon Pharmaceuticals Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $428.7M.
How much revenue does Xenon Pharmaceuticals Inc. make?
Over the twelve months to September 30, 2026 Xenon Pharmaceuticals Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Xenon Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Xenon Pharmaceuticals Inc.'s next earnings report?
Xenon Pharmaceuticals Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare XENE with
Follow XENE
Get an email when Xenon Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Xenon Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.